Renin-angiotensin system inhibitors
Intervention2 papers4 findings
- Humans1
Outcomes
1Vascular dementia
no changein humans1HR 0.74Low certainty
1 study
Vascular dementia
no changein humans1HR 0.74Low certainty
Renin-angiotensin system inhibitors have no effect on vascular dementia in humans (HR 0.74, 95% CI 0.50-1.11).
Humansin adults with hypertensionmedian follow-up of 516 days
RAS inhibitors linked to lower dementia risk than CCBs · Drugs & aging · 28 Sep 2026
Associations
3Heart failure
downin humans1
1 study
Heart failure
downin humans1
Renin-angiotensin system inhibitors lower the risk of heart failure in humans.
Reviewin high-risk populations across the cardiovascular-kidney-metabolic spectrum
Pharmacological treatment strategies to prevent heart failure across the cardiovascular-kidney-metabolic spectrum: an EJHF Expert Consensus Statement · European journal of heart failure · 1 Oct 2026
Alzheimer's disease
downin humans1HR 0.59Low certainty
1 study
Alzheimer's disease
downin humans1HR 0.59Low certainty
Renin-angiotensin system inhibitors lower the risk of Alzheimer's disease in humans (HR 0.59, 95% CI 0.43-0.81).
Humansin adults with hypertensionmedian follow-up of 516 days
RAS inhibitors linked to lower dementia risk than CCBs · Drugs & aging · 28 Sep 2026
Dementia
downin humans1HR 0.68Low certainty
1 study
Dementia
downin humans1HR 0.68Low certainty
Renin-angiotensin system inhibitors lower the risk of dementia in humans (HR 0.68, 95% CI 0.55-0.84).
Humansin adults with hypertensionmedian follow-up of 516 days
RAS inhibitors linked to lower dementia risk than CCBs · Drugs & aging · 28 Sep 2026
Latest
2Pharmacological treatment strategies to prevent heart failure across the cardiovascular-kidney-metabolic spectrum: an EJHF Expert Consensus Statement
RAS inhibitors linked to lower dementia risk than CCBs
Incidence of all-cause dementia was 1.26 per 1000 person-years with RAS inhibitors versus 1.89 with calcium channel blockers (HR 0.68).Incidence of all-cause dementia was 1.26 per 1000 person-years with RAS inhibitors versus 1.89 with calcium channel blockers (HR 0.68).